Markel Corp boosted its position in shares of Allergan PLC. (NYSE:AGN) by 22.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,000 shares of the company’s stock after buying an additional 6,000 shares during the period. Markel Corp’s holdings in Allergan PLC. were worth $8,022,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Enterprise Financial Services Corp raised its position in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares in the last quarter. Jacobi Capital Management LLC raised its position in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares in the last quarter. JNBA Financial Advisors raised its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares in the last quarter. Webster Bank N. A. raised its position in Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock valued at $124,000 after buying an additional 123 shares in the last quarter. Finally, Pacific Center for Financial Services raised its position in Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock valued at $128,000 after buying an additional 475 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Allergan PLC. (NYSE:AGN) opened at 223.94 on Tuesday. The company has a market cap of $74.86 billion, a PE ratio of 6.82 and a beta of 1.16. The company has a 50-day moving average price of $240.49 and a 200 day moving average price of $238.48. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.35 earnings per share. On average, analysts forecast that Allergan PLC. will post $16.27 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be issued a $0.70 dividend. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.25%. Allergan PLC.’s dividend payout ratio is currently 9.95%.

WARNING: “Markel Corp Purchases 6,000 Shares of Allergan PLC. (AGN)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/29/markel-corp-purchases-6000-shares-of-allergan-plc-agn.html.

Several research firms have issued reports on AGN. BidaskClub lowered Allergan PLC. from a “sell” rating to a “strong sell” rating in a research note on Friday. Cantor Fitzgerald reiterated a “hold” rating on shares of Allergan PLC. in a research note on Tuesday, August 22nd. Argus reiterated a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a research note on Monday, August 14th. UBS AG reiterated an “outperform” rating and set a $275.00 price objective on shares of Allergan PLC. in a research note on Wednesday, August 9th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $278.00 price objective (up from $273.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $275.49.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.